GlassScriptPhysician profile
Stanley Kurek
NPI 1669577326
$14,947.69
in general payments reported to CMS, 2019-2025
12 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,393 · 2020: $6,263 · 2021: $2,192 · 2022: $334 · 2023: $162 · 2024: $35.10 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Z-Medica, LLC | $7,342.30 | 2019-2021 | |
| Acell, INC. | $5,011.87 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,064.24 | 2021-2023 | Matrixrib |
| Teleflex LLC | $592.82 | 2021-2022 | |
| Aroa Biosurgery Incorporated | $531.73 | 2025 | |
| Integra Lifesciences Corporation | $128.07 | 2021 | |
| Depuy Synthes Sales INC. | $87.93 | 2021 | |
| Davol INC. | $51.84 | 2020 | |
| Ethicon US, LLC | $50.41 | 2022-2025 | Megadyne |
| Hemosonics LLC | $35.10 | 2024 | Quantra Qplus System, Qunatra Qplus System |
| Astrazeneca Pharmaceuticals LP | $34.98 | 2023 | Andexxa |
| Haemonetics Corporation | $16.40 | 2023 | Teg6s Hemostasis System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Kurek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.